Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial

We observed that the prognostic relation of BMI changes according to the type of adjuvant ET and mode of administration of extended AI. This warrants further investigation.

Authors

Institutions

Publication Details

Journal
European Journal of Cancer
Published
2025-04-17
DOI
https://doi.org/10.1016/j.ejca.2025.115438
Citations
1
Primary Topic
Cancer Risks and Factors
Type
article
Field-Weighted Citation Impact
1.05

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial

Patrick Neven, Erika Hitre, Giacomo Biganzoli, Marion Maetens et al.
1 citations
European Journal of Cancer
Cancer Risks and Factors
1.05
article

Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial

Patrick Neven, Erika Hitre, Giacomo Biganzoli, Marion Maetens, Meredith M. Regan, Alastair Mark Thompson, Elisabetta Munzone, Stefan Aebi, François Richard, Elia Mario Biganzoli, Christine Desmedt, Roswitha Kammler, Marco Colleoni, Patrizia Boracchi, Giuseppe Floris, Guy Jérusalem, Andrea Gombos, Edoardo Isnaldi, Patrizia Dell'Orto, Giuseppe Marano, Giuseppe Viale
article en
1 citations

Abstract

We observed that the prognostic relation of BMI changes according to the type of adjuvant ET and mode of administration of extended AI. This warrants further investigation.

European Journal of CancerVol. 222
Université Libre de Bruxelles (BE), University of Liège (BE), University of Lucerne (CH), Baylor College of Medicine (US), University of Milan (IT), Breast Cancer Research Foundation (US), Universitair Ziekenhuis Leuven (BE), Institut Jules Bordet (BE), VIB-KU Leuven Center for Cancer Biology (BE), Molecular Partners (Switzerland) (CH), Dana-Farber Cancer Institute (US), National Institute of Oncology (HU), IBM (Italy) (IT), Children's Cancer Center (US), Istituti di Ricovero e Cura a Carattere Scientifico (IT), International Breast Cancer Study Group (CH), European Institute of Oncology (IT), KU Leuven (BE)
Oncosuisse, Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung
Good health and well-being
Openalex Percentile: Top 23%
Cancer Risks and Factors
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.